PULSE BIOSCIENCES, INC. STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANTStock Option Agreement • May 15th, 2024 • Pulse Biosciences, Inc. • Surgical & medical instruments & apparatus • California
Contract Type FiledMay 15th, 2024 Company Industry JurisdictionUnless otherwise defined herein, the terms defined in the Pulse Biosciences, Inc. Amended and Restated 2017 Inducement Equity Incentive Plan (the “Plan” of the “2017 Inducement Equity Incentive Plan”)) will have the same defined meanings in this Stock Option Agreement including the Notice of Stock Option Grant (the “Notice of Grant”), the Terms and Conditions of Stock Option Grant, and the appendices and exhibits attached thereto (all together, the “Award Agreement”).
PULSE BIOSCIENCES, INC. FIFTH AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 15th, 2024 • Pulse Biosciences, Inc. • Surgical & medical instruments & apparatus • California
Contract Type FiledMay 15th, 2024 Company Industry JurisdictionThis fifth amendment (this “Amendment”) is entered into effective as of May 12, 2024, by and between Darrin Uecker (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”).
PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 15th, 2024 • Pulse Biosciences, Inc. • Surgical & medical instruments & apparatus • California
Contract Type FiledMay 15th, 2024 Company Industry JurisdictionThis Employment Agreement (the “Agreement”) is made and entered into by and between Burke T. Barrett (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of May 12, 2024. Certain capitalized terms used herein shall have the meanings assigned to them in Section 10 of this Agreement.
PULSE BIOSCIENCES, INC. FOURTH AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 15th, 2024 • Pulse Biosciences, Inc. • Surgical & medical instruments & apparatus • California
Contract Type FiledMay 15th, 2024 Company Industry JurisdictionThis fourth amendment (this “Amendment”) is entered into effective as of May 12, 2024, by and between Kevin Danahy (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”).